Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer's Disease
Renã A S Robinson1, Bushra Amin2, Paul C Guest3
1Department of Chemistry, University of Pittsburgh, Pittsburgh, PA, 15260, USA. rena@pitt.edu.
Advances in Experimental Medicine and Biology
|March 30, 2017
Summary
Alzheimer's disease (AD) research is advancing, but single biomarkers are insufficient due to the disease's complexity. Multiplex proteomic assays show promise for diagnosing and predicting AD progression.
Area of Science:
- Neuroscience
- Biochemistry
- Medical Diagnostics
Background:
- Alzheimer's disease (AD) affects millions globally, presenting complex multifactorial symptoms beyond cognitive decline.
- Current diagnostic challenges stem from AD's complexity and the limited clinical translation of molecular biomarkers.
- Established CSF biomarkers include amyloid-beta 1-42, total tau, and hyperphosphorylated tau (p-tau).
Purpose of the Study:
- To review proteomic biomarker assays for Alzheimer's disease.
- To highlight the potential of these assays in clinical diagnosis and prognosis.
- To emphasize the need for multiplex approaches in AD biomarker discovery.
Main Methods:
- Review of current literature on Alzheimer's disease biomarkers.
- Focus on proteomic analyses of bodily fluids, including plasma.
- Discussion of multiplex immunoassay and mass spectrometry-based proteomics platforms.
Main Results:
- Single biomarker assays are insufficient for complex diseases like AD.
- Proteomics offers a growing number of potential biomarker candidates in various body fluids.
- Multiplex biomarker tests are essential for comprehensive AD diagnosis, prevention, and prognosis.
Conclusions:
- Proteomic biomarker assays are crucial for advancing Alzheimer's disease research.
- Multiplex approaches are necessary to overcome the limitations of single biomarker assays.
- Proteomic analysis holds significant potential for clinical applications in AD diagnosis and prognosis.
